Leaders in government, business, and society all seek to adopt policies that will spur the development of treatments and preventive therapies for COVID-19 that can be delivered as rapidly as possible in an affordable and equitable manner. One critical issue will be how new treatments will be priced to ensure that this goal can be met. In the exceptional circumstances of the coronavirus pandemic the early decisions made regarding pricing policy will guide further decisions in the coming months that will have enormous consequences for the United States and the rest of the world.
The Institute for Clinical and Economic Review is hosting a three-part colloquium series of 90-minute webinars with policy makers and experts from diverse perspectives to debate alternative pricing policy approaches for current and future treatments for COVID-19.
The third colloquium will cover monetary prizes, compulsory licensing, and advanced market commitments, approaches being considered by some foreign countries as needed to manage the development and pricing of effective treatments in a public health emergency
Confirmed speakers include:
- Peter Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- James Love, MPA, Director, Knowledge Ecology International
- Nicole Lurie, MD, MSPH, Strategic Advisor to the CEO, Coalition for Epidemic Preparedness Innovations, and Former Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services during the Obama Administration
- Carl Schmid, Executive Director, HIV + Hepatitis Policy Institute.